BACKGROUND:Nicotine alters auditory event-related potentials (ERPs) in rodents and humans and is an effective treatment for smoking cessation. Less is known about the effects of the partial nicotine agonist varenicline on ERPs. METHODS: We measured the effects of varenicline and nicotine on the mouse P20 and varenicline and smoking on the human P50 in a paired-click task. Eighteen mice were tested following nicotine, varenicline, and their combination. One hundred and fourteen current smokers enrolled in aplacebo-controlled within-subject crossover study to test the effects of varenicline during smoking and abstinence. Thirty-two subjects participated in the ERP study, with half receiving placebo first and half varenicline first (VP). RESULTS:Nicotine and varenicline enhanced mouse P20 amplitude, while nicotine improved P20 habituation by selectively increasing the first-click response. Similar to mice, abstinence reduced P50 habituation relative to smoking by reducing the first-click response. There was no effect of varenicline on P50 amplitude during abstinence across subjects. However, there was a significant effect of medication order on P50 amplitude during abstinence. Subjects in the PV group displayed reduced P50 during abstinence, which was blocked by varenicline. However, subjects in the VP group did not display abstinence-induced P50 reduction. CONCLUSIONS: Data suggest that smoking improves sensory processing. Varenicline mimics amplitude changes associated with nicotine and smoking but fails to alter habituation. The effect of medication order suggests a possible carryover effect from the previous arm. This study supports the predictive validity of ERPs in mice as a marker of drug effects in human studies.
RCT Entities:
BACKGROUND:Nicotine alters auditory event-related potentials (ERPs) in rodents and humans and is an effective treatment for smoking cessation. Less is known about the effects of the partial nicotine agonist varenicline on ERPs. METHODS: We measured the effects of varenicline and nicotine on the mouseP20 and varenicline and smoking on the humanP50 in a paired-click task. Eighteen mice were tested following nicotine, varenicline, and their combination. One hundred and fourteen current smokers enrolled in a placebo-controlled within-subject crossover study to test the effects of varenicline during smoking and abstinence. Thirty-two subjects participated in the ERP study, with half receiving placebo first and half varenicline first (VP). RESULTS:Nicotine and varenicline enhanced mouseP20 amplitude, while nicotine improved P20 habituation by selectively increasing the first-click response. Similar to mice, abstinence reduced P50 habituation relative to smoking by reducing the first-click response. There was no effect of varenicline on P50 amplitude during abstinence across subjects. However, there was a significant effect of medication order on P50 amplitude during abstinence. Subjects in the PV group displayed reduced P50 during abstinence, which was blocked by varenicline. However, subjects in the VP group did not display abstinence-induced P50 reduction. CONCLUSIONS: Data suggest that smoking improves sensory processing. Varenicline mimics amplitude changes associated with nicotine and smoking but fails to alter habituation. The effect of medication order suggests a possible carryover effect from the previous arm. This study supports the predictive validity of ERPs in mice as a marker of drug effects in human studies.
Authors: S Shiffman; J A Johnston; M Khayrallah; C A Elash; C J Gwaltney; J A Paty; M Gnys; G Evoniuk; J DeVeaugh-Geiss Journal: Psychopharmacology (Berl) Date: 2000-01 Impact factor: 4.530
Authors: L Elliot Hong; Gunvant K Thaker; Robert P McMahon; Ann Summerfelt; Jill Rachbeisel; Rebecca L Fuller; Ikwunga Wonodi; Robert W Buchanan; Carol Myers; Stephen J Heishman; Jeff Yang; Adrienne Nye Journal: Arch Gen Psychiatry Date: 2011-08-01
Authors: Robert E Featherstone; Jennifer M Phillips; Tony Thieu; Richard S Ehrlichman; Tobias B Halene; Steven C Leiser; Edward Christian; Edwin Johnson; Caryn Lerman; Steven J Siegel Journal: PLoS One Date: 2012-07-20 Impact factor: 3.240
Authors: Tatiana A Stroganova; Vladimir V Kozunov; Irina N Posikera; Ilia A Galuta; Vitaliy V Gratchev; Elena V Orekhova Journal: PLoS One Date: 2013-07-25 Impact factor: 3.240
Authors: Robert E Lin; Lauren Ambler; Eddie N Billingslea; Jimmy Suh; Shweta Batheja; Valerie Tatard-Leitman; Robert E Featherstone; Steven J Siegel Journal: Physiol Rep Date: 2013-10-20